Insider Selling: uniQure (NASDAQ:QURE) Insider Sells 1,434 Shares of Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 1,434 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $46.86, for a total value of $67,197.24. Following the sale, the insider directly owned 168,235 shares in the company, valued at $7,883,492.10. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00.

uniQure Trading Down 2.8%

Shares of uniQure stock traded down $1.33 during trading hours on Tuesday, hitting $46.06. The company’s stock had a trading volume of 2,046,725 shares, compared to its average volume of 2,756,366. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The stock has a 50 day moving average of $28.45 and a 200 day moving average of $23.22. The company has a market capitalization of $2.91 billion, a PE ratio of -13.24 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. Analysts predict that uniQure N.V. will post -3.65 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on QURE shares. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research note on Friday. Royal Bank Of Canada increased their target price on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $64.17.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System lifted its stake in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares during the last quarter. Ensign Peak Advisors Inc grew its position in shares of uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares during the period. FNY Investment Advisers LLC grew its position in shares of uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the period. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $50,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.